GeneOne Life Science
GeneOne Life Science is a global leader in the research, development, and manufacturing of nucleic-acid based vaccines, therapeutics, and novel small molecule drugs. The company focuses on next-generation biopharmaceuticals, including DNA and RNA vaccines for emerging infectious diseases, and nucleic acid therapeutics such as monoclonal antibodies and recombinant proteins. With a strong emphasis on innovation, quality, and integrity, GeneOne aims to improve human health worldwide and establish itself as a leading biotech company.
Industries
Nr. of Employees
small (1-50)
GeneOne Life Science
07335 Seoul, Yeongdeungpo-gu, Yeouidaero 108, 20th Floor, Park One NH Financial Tower (Tower 2)
Products
Nucleic-acid vaccine pipeline for multiple viral diseases
Pipeline of DNA- and RNA-based vaccine candidates targeting a range of viral diseases (including coronaviruses, flaviviruses and tick-borne viruses) at preclinical and early clinical stages.
Plasmid-encoded therapeutics and recombinant protein programs
R&D programs delivering recombinant proteins and monoclonal antibodies via plasmid vectors for oncology, hemophilia, hepatitis and autoimmune indications; programs in discovery and early development.
Small-molecule immunomodulators and nasal spray programs
Small-molecule candidates for inflammatory and infectious respiratory/renal conditions and nasal spray formulations that stimulate epithelial innate immunity for prophylaxis and treatment.
Nucleic-acid vaccine pipeline for multiple viral diseases
Pipeline of DNA- and RNA-based vaccine candidates targeting a range of viral diseases (including coronaviruses, flaviviruses and tick-borne viruses) at preclinical and early clinical stages.
Plasmid-encoded therapeutics and recombinant protein programs
R&D programs delivering recombinant proteins and monoclonal antibodies via plasmid vectors for oncology, hemophilia, hepatitis and autoimmune indications; programs in discovery and early development.
Small-molecule immunomodulators and nasal spray programs
Small-molecule candidates for inflammatory and infectious respiratory/renal conditions and nasal spray formulations that stimulate epithelial innate immunity for prophylaxis and treatment.
Services
Commercial and clinical-grade production of high-purity plasmid DNA and support for mRNA manufacturing including IVT template supply, scale-up, and cGMP quality systems.
Support for preclinical immunogenicity and challenge studies, translation to Phase I/IIa trials, clinical trial conduct and generation of peer-reviewed clinical data.
Discovery, formulation and clinical development support for small-molecule anti-inflammatory candidates and topical nasal sprays targeting innate immune pathways.
Commercial and clinical-grade production of high-purity plasmid DNA and support for mRNA manufacturing including IVT template supply, scale-up, and cGMP quality systems.
Support for preclinical immunogenicity and challenge studies, translation to Phase I/IIa trials, clinical trial conduct and generation of peer-reviewed clinical data.
Discovery, formulation and clinical development support for small-molecule anti-inflammatory candidates and topical nasal sprays targeting innate immune pathways.
Expertise Areas
- Nucleic-acid vaccine development
- Plasmid-based therapeutics and DNA-encoded antibodies
- cGMP plasmid and mRNA manufacturing and CDMO services
- Preclinical immunology and animal challenge models (rodent and ferret)
Key Technologies
- Plasmid vector design and optimization
- In vitro transcription (IVT) workflows for mRNA production
- High-purity plasmid DNA cGMP production
- Automated mixing-based bioprocess for plasmid manufacture